Ezetimibe/rosuvastatin

Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol.^[6][7] In some countries it is sold as a kit or a pack containing two distinct pills.^[8][9]

Ezetimibe/rosuvastatin

Ezetimibe (top) and rosuvastatin (bottom)
Combination of
Ezetimibe	Hypolipidemic agent
Rosuvastatin	Statin
Clinical data
Trade names	Ridutrink, Roszet, others
AHFS/Drugs.com	Multum Consumer Information
License data	US DailyMed: Ezetimibe and rosuvastatin
Pregnancy category	AU: D[1]
Routes of administration	By mouth
ATC code	C10BA06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1][2] US: ℞-only[3][4] EU: Rx-only[5] In general: ℞ (Prescription only)
Identifiers
KEGG	D11520

The combination was approved for medical use in the United States in March 2021.^[4]

Medical uses

Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.^[10]

Pharmacology

Ezetimibe/rosuvastatin combines two lipid-lowering therapies.

• Ezetimibe inhibits NPC1L1, the transporter that is responsible for absorption of dietary cholesterol from the intestine.^[3]
• Rosuvastatin inhibits HMG-CoA reductase, an enzyme involved in synthesis of new cholesterol in the liver.^[3]